SAN FRANCISCO, Feb. 13, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the Bank of America Merrill Lynch (BAML) Animal Health Summit on February 25 in New York City and at the Barclays Global Healthcare Conference on March 12 in Miami.
During this time, investors will have the opportunity to discuss recent developments, including the launch of KindredBio's first product, key therapeutic programs in development, and upcoming milestones.
Conference Details:
BAML Animal Health Summit
Date: Monday, February 25, 2019
KindredBio participant: Richard Chin, Chief Executive Officer
Presentation time: 9:25-10:05 AM ET
Location: Bank of America Tower, One Bryant Park, 51st Floor, NY
Webcast URL: Click here
Barclays Global Healthcare Conference
Date: Tuesday, March 12, 2019
KindredBio participant: Denise Bevers, President and Chief Operating Officer
Presentation time: 2:05-2:30 PM ET
Location: Loews Miami Beach Hotel, Miami Beach, FL
Webcast URL: Click here
An archived version of the above webcasts will be available for 30 days on the Company's website.
About Kindred Biosciences
Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. KindredBio's first approved drug is Mirataz® (mirtazapine transdermal ointment) for the management of weight loss in cats.
Important Safety Information
Mirataz® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients or in cats treated with monoamine oxidase inhibitors (MAOIs). Not for human use. Keep out of reach of children. Wear gloves to apply and wash hands after. Avoid contact with treated cat for 2 hours following application. The most common adverse reactions include application site reactions, behavioral abnormalities (vocalization and hyperactivity) and vomiting. Please see the full Prescribing Information.
Contact
Katja Buhrer
katja.buhrer@kindredbio.com
(917) 969-3438
SOURCE Kindred Biosciences, Inc.
